We show that the anti-Rgp antibody response is elevated in ACPA-positive at-risk individuals with MSK-C compared with HC, with stable levels during the risk phase, in both progressors and those who remained arthritis-free during the study period. This evidence concerns the gene PRTN3 and arthritic joint disease.